文献速递腹部技术与安全CT

胃癌化疗后术前肿瘤再分期与可切除性评估:采用新分期标准的MDCT诊断准确性

Preoperative tumor restaging and resectability assessment of gastric cancers after chemotherapy: diagnostic accuracy of MDCT using new staging criteria.
PubMed 文献 · Abdom Radiol (NY) · 2017-01-01

回顾性纳入37例初始不可切除胃癌化疗后手术患者,由两名放射科医师独立阅片,采用新分期标准(不将非强化胃周浸润、非强化淋巴结、远处转移明显缩小后残留的细微浸润分别用于T、N、M分期升级)评估TNM再分期及5分法可切除性。预测可切除性的ROC曲线下面积分别为0.885和0.882,观察者间一致性加权κ=0.689;共识阅片对T4b、N阳性、M1的敏感度/特异度分别为80.0%(4/5)/100%(29/29)、35.3%(6/17)/81.3%(13/16)、63.6%(7/11)/100%(26/26)。

要点

  • 新标准下MDCT预测可切除性AUC为0.885和0.882,观察者间一致性加权κ=0.689。
  • 共识阅片对T4b特异度100%(29/29),敏感度80.0%(4/5)。
  • 共识阅片对M1特异度100%(26/26),敏感度63.6%(7/11)。

核心结论

  • 对化疗后胃癌,新MDCT标准对T4b和M分期显示高特异度,对转化手术前预测可切除性表现良好。

研究设计与样本

  • 回顾性研究,经本院机构审查委员会批准并豁免知情同意,纳入37例初始不可切除胃癌化疗后接受手术的患者。
  • 两名独立放射科医师审阅术前MDCT图像确定TNM分期并以5分法(5分:肯定不可切除,1分:肯定可切除)评定整体可切除可能性,TNM分期不一致由第三名审阅者解决。
  • 新化疗后MDCT标准不使用非强化胃周浸润、非强化淋巴结及远处转移明显缩小后残留的细微浸润分别用于T、N、M分期升级。
  • 以病理结果或手术记录为参考标准评估MDCT诊断性能。

诊断标准与关键数值

  • 预测可切除性AUC:审阅者1为0.885(95%CI 0.737-0.966),审阅者2为0.882(95%CI 0.733-0.964),观察者间一致性加权κ=0.689。
  • 共识阅片T4b:敏感度80.0%(4/5),特异度100%(29/29)。
  • 共识阅片N阳性:敏感度35.3%(6/17),特异度81.3%(13/16)。
  • 共识阅片M1:敏感度63.6%(7/11),特异度100%(26/26)。

临床应用与阅片要点

  • 新MDCT标准不将非强化胃周浸润、非强化淋巴结及远处转移明显缩小后残留的细微浸润分别用于T、N、M分期升级。
  • 可切除性采用5分法评定(5分:肯定不可切除,1分:肯定可切除)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

PURPOSE: To evaluate the diagnostic performance of preoperative MDCT for tumor restaging and determination of resectability in gastric cancers after chemotherapy using new staging criteria.

METHODS: This retrospective study was approved by our institutional review board and the requirement for informed consent was waived. Thirty-seven patients with initially unresectable gastric cancers who had received chemotherapy followed by surgery were included. Two independent radiologists reviewed preoperative MDCT images to determine the TNM staging and rate the overall likelihood of resectability using a 5-point scale (5: definitely unresectable, 1: definitely resectable). New post-chemotherapy MDCT criteria do not use non-enhancing perigastric infiltrations, non-enhancing lymph nodes (LNs), and subtle remaining infiltrations after marked decrease in the size of distant metastases for T, N, and M upstaging, respectively. Discrepancies in TNM staging were resolved by a third reviewer. The diagnostic performances of MDCT were assessed using pathologic results or operation records as reference standards.

RESULTS: For predicting resectability, the areas under the ROC curve were 0.885 and 0.882 (95% CIs 0.737-0.966 and 0.733-0.964) in reviewers 1 and 2, respectively, with substantial inter-reader agreement (weighted κ = 0.689). Sensitivities and specificities of MDCT for tumor restaging on a consensus review were 80.0% (4/5) and 100% (29/29) for T4b, 35.3% (6/17) and 81.3% (13/16) for N-positive, and 63.6% (7/11) and 100% (26/26) for M1, respectively.

CONCLUSIONS: For gastric cancers after chemotherapy, new MDCT criteria demonstrated high specificities for T4b and M-staging and good performances to predict resectability before conversion surgery.

来源:Abdom Radiol (NY),查看原文。版权归原作者所有。

引用

  1. Joo I, Kim SH, Ahn SJ, et al. Preoperative tumor restaging and resectability assessment of gastric cancers after chemotherapy: diagnostic accuracy of MDCT using new staging criteria. Abdom Radiol (NY). 2017. PMID: 28643135. doi:10.1007/s00261-017-1224-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。